Debu Tripathy, MD | Authors


Explaining PFS2 in the MONALEESA-7 Trial for HR+/HER2- Breast Cancer

July 03, 2019

Debu Tripathy, MD, of the Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, was an investigator in the phase III MONALEESA-7 trial. The purpose of the study was to examine how endocrine therapy, in combination with a cyclin-dependent kinase inhibitor, affects progression-free survival and overall survival in premenopausal patients with HR-positive, HER2-negative advanced breast cancer.

Tripathy Discusses a Study of Talazoparib in BRCA-Mutated Advanced Breast Cancer

June 06, 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the phase II ABRAZO study of talazoparib following platinum or multiple cytotoxic regimens in advanced breast cancer patients with germline BRCA 1/2 mutations during the 2017 ASCO Annual Meeting.